4-(4-fluoro-2-methylphenyl)piperidine hydrochloride | 218450-26-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(4-fluoro-2-methylphenyl)piperidine hydrochloride
• 英文别名: 4-(2-methyl-4-fluorophenyl)piperidine hydrochloride；4-(4-Fluoro-2-methylphenyl)piperidine;hydrochloride
• CAS: 218450-26-1
• 化学式: C₁₂H₁₆FN*ClH
• 分子量: 229.725
• InChiKey: QUJXSWPFBHFPPQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.02
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Hydroxamate sulfonamides as cd23 shedding inhibitors
  申请人：Owen Alan David

  公开号：US20060276507A1

  公开（公告）日：2006-12-07

  A class of piperidine and related heterocyclic derivatives, C-substituted by a substituted aryl or heteroaryl moiety, and N-substituted by an ethylsulfonyl group which in turn is substituted at the 2-position by a hydroxamic acid moiety and also by a range of alternative substituents, being potent inhibitors of CD23 shedding, are useful in the treatment and/or prevention of allergic, inflammatory and neoplastic diseases.

  一类由吡啶和相关杂环衍生物组成，C位被取代芳基或杂芳基基团取代，N位被乙基磺酰基取代，该基团在2位被羟肟酸基团和一系列替代基团取代，是CD23剪切的有效抑制剂，可用于治疗和/或预防过敏性、炎症性和肿瘤性疾病。
• BENZIMIDAZOLYL COMPOUNDS
  申请人：Efremov Ivan

  公开号：US20080280933A1

  公开（公告）日：2008-11-13

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本文披露了化合物及其药学上可接受的盐，其中化合物的结构如规范中所定义的I式。还披露了相应的制药组合物、治疗方法、合成方法和中间体。
• AZABENZIMIDAZOLYL COMPOUNDS
  申请人：Efremov Ivan

  公开号：US20080312271A1

  公开（公告）日：2008-12-18

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  该专利公开了化合物及其药学上可接受的盐，其中该化合物的结构式定义如说明书中的式I。同时公开了相应的药物组合物、治疗方法、合成方法和中间体。
• HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS
  申请人：Celltech R & D Limited

  公开号：EP1648868B1

  公开（公告）日：2006-11-15